We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+7.58%
1 Year Est. Return
+80.99%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$4.62B
AUM Growth
Cap. Flow
+$4.56B
Cap. Flow %
98.7%
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$400M
2
AAPL icon
Apple
AAPL
+$352M
3
MSFT icon
Microsoft
MSFT
+$326M
4
AMZN icon
Amazon
AMZN
+$218M
5
META icon
Meta Platforms (Facebook)
META
+$195M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Technology 45.41%
2 Consumer Discretionary 17.29%
3 Communication Services 14.35%
4 Healthcare 6.6%
5 Consumer Staples 4.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PRME icon
576
Prime Medicine
PRME
$547M
$7.88K ﹤0.01%
+2,700
New +$9.48K
ALMS
577
Alumis Inc
ALMS
$3.36B
$7.8K ﹤0.01%
+992
New +$9.94K
SANA icon
578
Sana Biotechnology
SANA
$882M
$7.64K ﹤0.01%
+4,688
New +$14K
TSHA icon
579
Taysha Gene Therapies
TSHA
$1.61B
$7.44K ﹤0.01%
+4,303
New +$8.93K
YMAB
580
DELISTED
Y-mAbs Therapeutics
YMAB
$7.36K ﹤0.01%
+940
New +$11.4K
DSGN icon
581
Design Therapeutics
DSGN
$751M
$7.34K ﹤0.01%
+1,189
New +$6.88K
PKST
582
DELISTED
Peakstone Realty Trust
PKST
$7.26K ﹤0.01%
+656
New +$8.55K
SVC
583
Service Properties Trust
SVC
$1.05B
$7.22K ﹤0.01%
+568
New +$9.18K
CRVS icon
584
Corvus Pharmaceuticals
CRVS
$1.1B
$7.22K ﹤0.01%
+1,349
New +$10.1K
NGNE icon
585
Neurogene
NGNE
$672M
$7.13K ﹤0.01%
+312
New +$11.6K
OLMA icon
586
Olema Pharmaceuticals
OLMA
$977M
$7.01K ﹤0.01%
+1,203
New +$12K
DHC
587
Diversified Healthcare Trust
DHC
$2.15B
$6.98K ﹤0.01%
+3,036
New +$8.94K
SAGE
588
DELISTED
Sage Therapeutics
SAGE
$6.97K ﹤0.01%
+1,284
New +$7.85K
TNGX icon
589
Tango Therapeutics
TNGX
$4.21B
$6.97K ﹤0.01%
+2,255
New +$10.5K
HPP
590
Hudson Pacific Properties
HPP
$758M
$6.95K ﹤0.01%
+327
New +$8.94K
AQST icon
591
Aquestive Therapeutics
AQST
$452M
$6.81K ﹤0.01%
+1,914
New +$8.83K
SLN
592
Silence Therapeutics
SLN
$546M
$6.79K ﹤0.01%
+987
New +$12.7K
RVNC
593
DELISTED
Revance Therapeutics, Inc.
RVNC
$6.7K ﹤0.01%
+2,203
New +$9.6K
LAND
594
Gladstone Land Corp
LAND
$365M
$6.66K ﹤0.01%
+614
New +$7.61K
TRVI icon
595
Trevi Therapeutics
TRVI
$2.57B
$6.65K ﹤0.01%
+1,614
New +$5.17K
SLRN
596
DELISTED
ACELYRIN
SLRN
$6.62K ﹤0.01%
+2,107
New +$10.2K
CBL
597
CBL Properties
CBL
$1.84B
$6.53K ﹤0.01%
+222
New +$6.29K
VYGR icon
598
Voyager Therapeutics
VYGR
$181M
$6.5K ﹤0.01%
+1,147
New +$7.39K
ABSI icon
599
Absci
ABSI
$1.17B
$6.32K ﹤0.01%
+2,412
New +$8.49K
RIGL icon
600
Rigel Pharmaceuticals
RIGL
$723M
$6.22K ﹤0.01%
+370
New +$7.1K

Similar funds

GF Fund Management's Q4 2024 Portfolio in Review

Q4 2024 is the first quarter with a 13F filing on record for GF Fund Management, which disclosed 637 positions worth $4.62B. Its ten largest holdings account for 48% of the portfolio.

Its largest position is NVIDIA: 2,904,119 shares worth $390M.

By sector, the portfolio is most concentrated in Technology at 45% of assets, followed by Consumer Discretionary and Communication Services.

  • GF Fund Management's largest Q4 2024 buy was NVIDIA: 2,904,119 shares worth $390M.
  • GF Fund Management's ten largest holdings make up 48% of its $4.62B portfolio in Q4 2024.
  • GF Fund Management disclosed 637 positions in Q4 2024, its first 13F filing on record.

Based on GF Fund Management's 13F filing for Q4 2024, filed 19 Feb 2025.